iBio Announces New Investments from Board Members and Officers
iBio (NYSEA: IBIO) has secured over $650,000 through a private placement offering from its Board of Directors and Officers. The investment demonstrates internal confidence in the company's strategy as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases and obesity.
The company is developing breakthrough antibody treatments designed to promote healthy weight loss while preserving and promoting muscle mass, and preventing weight regain. These therapeutics are being developed using iBio's machine-learning-based drug discovery platform, with a focus on high developability and extended half-life to potentially reduce dosing frequency compared to current obesity treatments.
iBio (NYSEA: IBIO) ha ottenuto oltre $650.000 tramite un'offerta di collocamento privato dal suo Consiglio di Amministrazione e dai Dirigenti. L'investimento dimostra la fiducia interna nella strategia dell'azienda come biotech in fase clinica, concentrata sullo sviluppo di terapie per le malattie cardiometaboliche e l'obesità.
L'azienda sta sviluppando trattamenti antibodiali rivoluzionari progettati per promuovere una perdita di peso sana, preservando e promuovendo la massa muscolare e prevenendo il recupero del peso. Queste terapie vengono sviluppate utilizzando la piattaforma di scoperta di farmaci basata su machine learning di iBio, focalizzandosi su una grande sviluppabilità e un'emivita prolungata per ridurre potenzialmente la frequenza delle somministrazioni rispetto ai trattamenti attuali per l'obesità.
iBio (NYSEA: IBIO) ha asegurado más de $650,000 a través de una oferta de colocación privada de su Junta Directiva y Funcionarios. La inversión demuestra la confianza interna en la estrategia de la empresa como una biotech en etapa clínica enfocada en desarrollar terapias para enfermedades cardiometabólicas y obesidad.
La empresa está desarrollando tratamientos antibodiales innovadores diseñados para promover una pérdida de peso saludable mientras preserva y promueve la masa muscular, así como previene el aumento de peso. Estas terapias se están desarrollando utilizando la plataforma de descubrimiento de fármacos basada en aprendizaje automático de iBio, centrando la atención en una alta capacidad de desarrollo y una vida media extendida para potencialmente reducir la frecuencia de dosificación en comparación con los tratamientos actuales para la obesidad.
iBio (NYSEA: IBIO)는 이사회 및 임원으로부터 사모 배치를 통해 $650,000 이상을 확보했습니다. 이 투자는 심혈관 대사 질환 및 비만을 위한 치료제를 개발하는 임상 단계 바이오텍 회사의 전략에 대한 내부 신뢰를 보여줍니다.
회사는 건강한 체중 감소를 촉진하고 근육량을 유지 및 촉진하며 체중 재증가를 방지하기 위해 설계된 획기적인 항체 치료제를 개발하고 있습니다. 이러한 치료제는 iBio의 기계 학습 기반 약물 발견 플랫폼을 사용하여 개발되고 있으며, 현재의 비만 치료제에 비해 투여 빈도를 줄일 수 있도록 높은 개발 잠재력과 연장된 반감기에 중점을 두고 있습니다.
iBio (NYSEA: IBIO) a sécurisé plus de $650,000 grâce à une offre de placement privé de son Conseil d'Administration et de ses Dirigeants. Cet investissement démontre une confiance interne dans la stratégie de l'entreprise en tant que biotech en phase clinique, axée sur le développement de thérapies pour les maladies cardiométaboliques et l'obésité.
L'entreprise développe des traitements anticorps révolutionnaires conçus pour promouvoir une perte de poids saine tout en préservant et en favorisant la masse musculaire, et en prévenant la reprise de poids. Ces thérapeutiques sont développées à l'aide de la plateforme de découverte de médicaments basée sur l'apprentissage automatique d'iBio, avec un accent sur une grande développabilité et une demi-vie prolongée pour potentiellement réduire la fréquence des dosages par rapport aux traitements actuels de l'obésité.
iBio (NYSEA: IBIO) hat über $650.000 durch ein privates Platzierungsangebot von seinem Vorstand und den Führungskräften gesichert. Die Investition zeigt das interne Vertrauen in die Strategie des Unternehmens als klinische Biotech-Firma, die sich auf die Entwicklung von Therapeutika für kardiometabolische Erkrankungen und Adipositas konzentriert.
Das Unternehmen entwickelt bahnbrechende Antikörperbehandlungen, die darauf ausgelegt sind, einen gesunden Gewichtsverlust zu fördern, während die Muskelmasse bewahrt und gefördert wird und eine Gewichtszunahme verhindert wird. Diese Therapeutika werden mithilfe von iBio's maschinenlernenden Arzneimittelentdeckungsplattform entwickelt, mit einem Fokus auf hoher Entwickelbarkeit und verlängerter Halbwertszeit, um die Dosierfrequenz im Vergleich zu aktuellen Adipositasbehandlungen potenziell zu reduzieren.
- Secured $650,000 in new funding through private placement
- Strong internal confidence demonstrated through Board and Officer investments
- Development of therapeutics with potential advantages over current obesity treatments
- AI-driven platform enabling development of extended half-life therapeutics
- Small funding amount relative to typical biotech development costs
- Reliance on internal funding sources rather than external investors
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with members of its Board of Directors and Officers, totaling over
“We are grateful for the investments from our Board of Directors, which underscore their confidence and support in our strategy to advance as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases, obesity, and other challenging diseases,” said Martin Brenner, Ph.D., DVM, CEO and Chief Scientific Officer.
iBio is building an innovative pipeline of therapeutics in cardiometabolic disease and obesity that aims to promote healthy weight loss. These breakthrough antibody treatments are designed to reduce obesity while preserving muscle mass, promoting muscle growth, and preventing weight regain. iBio’s machine-learning-based drug discovery platform is driving the development of these candidates, which are being engineered for high developability and an extended half-life potentially enabling reduced dosing than current obesity therapeutics.
About iBio, Inc.
iBio (NYSEA: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the ability of iBio’s innovative pipeline of therapeutics in cardiometabolic disease and obesity to promote healthy weight loss, iBio’s antibody treatments reducing obesity while preserving muscle mass, promoting muscle growth and preventing weight regain, the successful engineering of iBio’s product candidates to have high developability and an extended half-life potentially enabling reduced dosing than current obesity therapeutics, and iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of iBio’s innovative pipeline of therapeutics in cardiometabolic disease and obesity to promote healthy weight loss; and iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
How much funding did iBio raise in its January 2025 private placement?
What therapeutic areas is iBio focusing on in 2025?
What advantages does iBio's obesity treatment aim to offer?
How is iBio developing its therapeutic candidates?
